Zbynek Schroner, Vladimír Uličiansky
Insulin glargin 300 U/ml is new basal insulin analog. Now it is coming to clinical practice also in Slovak Republic. It contains
a higher concentration of insulin than insuline glargin 100 U/ml. Insulin glargin 300 U/ml requires a smaller volume
of subcutaneous injection, it has a longer duration of action and plasma insulin exposure is less variable than insulin
glargin 100 U/ml. Clinical programme EDITION showed, that glargin 300 U/ml offers comparable glycaemic compensation
vs insulin glargin 100 U/ml. In comparison with patients who were randomised to insulin glargin 100 U/ml, in patients
with type 2 diabetes taking insulin glargin 300 U/ml, less hypoglycaemias mainly nocturnal and less weight gain
were recorded. Insulin glargin 300 U/ml is indicated for the treatment of adult type 1 and type 2 diabetics.